About Alexander Yule Consulting

 
Alexander Yule Consulting has provided commercial and corporate support and interim management services to the pharmaceutical and life sciences industries for over 20 years and prides itself on delivering cost-effective, high-quality and flexible assistance. The business benefits from an extensive network among the life sciences industry and close relationships with supporting legal and financial professionals.

The principal, Dr Alexander Yule, has worked at senior level, largely with early-stage and small to mid-cap life science and pharmaceutical companies (UK, Scandinavia and North America) and has first-hand experience of commercialising products and technologies in oncology, CNS, urology, vaccines, infectious disease, medical devices and OTC/consumer healthcare. 

He has acted on behalf of investors, buyers and sellers in conducting commercial due diligence and other support functions necessary for public listings, public and private placements and M&A transactions.
 
You can view the Principal's career history at :
 
Representative assignments in biotechology, pharmaceuticals and medical devices include:
  • Identification,due diligence and securing of of revenue-generating assets for a speciality pharmaceutical company (UK quoted)
  • Technology and market development forecasting for a global healthcare company (oncology, spinal injury)
  • Identification, definition and valuation of potential indications for a pre-clinical CNS asset (UK quoted company)
  • Identification, definition and valuation of potential indications for clinical stage dermatology and wound care assets (Swedish unlisted company)
  • Outlicensing of pre-clinical and late-stage oncology assets (both small molecule and biologic)
  • Outlicensing of late-stage novel urological pharmaceutical products and medical devices
  • Market modelling and competetive environment analyses for clinical-stage antibody therapeutics (oncology indications)
  • Valuation of a portfolio of novel anti-infective assets on behalf of the acquiring party
  • Review and valuation of a public company's intellectual property portfolio and know-how for spin-out into a privately-held medical technology company
  • Due diligence on behalf of investors and potential acquirers (in oncology, anti-inflammatory, vaccines, dermatology and other therapeutic areas)
  • Divestment of a privately-held CNS development company and its late-stage pipeline
  • Interim Chief Business Officer/Business Development Director (>6 month assignments) for a number of private and public companies  
Comments